Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/352841
COMPARTIR / EXPORTAR:
SHARE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Supplementary Material: Real-world evidence with a retrospective cohort of 15,968 COVID-19 hospitalized patients suggests 21 new effective treatments |
Autor: | Loucera, Carlos CSIC ORCID; Carmona, Rosario CSIC ORCID; Esteban-Medina, Marina CSIC ORCID; Bostelmann, Gerrit; Muñoyerro-Muñiz, Dolores; Villegas, Román; Peña-Chilet, María CSIC ORCID; Dopazo, Joaquín CSIC ORCID | Palabras clave: | Drug repurposing COVID-19 Real world data Real world evidence Retrospective cohort |
Fecha de publicación: | 6-oct-2023 | Editor: | BioMed Central Springer Nature |
Citación: | Loucera, Carlos; Carmona, Rosario; Esteban-Medina, Marina; Bostelmann, Gerrit; Muñoyerro-Muñiz, Dolores; Villegas, Román; Peña-Chilet, María; Dopazo, Joaquín; 2023; "Supplementary Material: Real-world evidence with a retrospective cohort of 15,968 COVID-19 hospitalized patients suggests 21 new effective treatments [Dataset]"; BMC; https://doi.org/10.1186/s12985-023-02195-9 | Resumen: | [Purpose] Despite the extensive vaccination campaigns in many countries, COVID-19 is still a major worldwide health problem because of its associated morbidity and mortality. Therefore, finding efficient treatments as fast as possible is a pressing need. Drug repurposing constitutes a convenient alternative when the need for new drugs in an unexpected medical scenario is urgent, as is the case with COVID-19. [Methods] Using data from a central registry of electronic health records (the Andalusian Population Health Database), the effect of prior consumption of drugs for other indications previous to the hospitalization with respect to patient outcomes, including survival and lymphocyte progression, was studied on a retrospective cohort of 15,968 individuals, comprising all COVID-19 patients hospitalized in Andalusia between January and November 2020. [Results] Covariate-adjusted hazard ratios and analysis of lymphocyte progression curves support a significant association between consumption of 21 different drugs and better patient survival. Contrarily, one drug, furosemide, displayed a significant increase in patient mortality. [Conclusions] In this study we have taken advantage of the availability of a regional clinical database to study the effect of drugs, which patients were taking for other indications, on their survival. The large size of the database allowed us to control covariates effectively. |
Descripción: | Supplementary Tables: Table S1. Data imported from BPS for each patient: code and definition of the variable.-- Table S2: Log Hazard ratios obtained for the drugs tested, along with standard deviations (SDs), upper and lower coefficient intervals (CI), nominal and FDR-adjusted p-values. Also, Lymphocyte proliferation values (see Methods) along with standard deviations (SDs), upper and lower coefficient intervals (CI), nominal and FDR-adjusted p-values. The two last columns indicate the drugs used in the machine learning drug repurposing prediction study and the proteins targeted by the drug. Targets marked with an * were those analyzed in the machine learning drug repurposing. | Versión del editor: | https://doi.org/10.1186/s12985-023-02195-9 | URI: | http://hdl.handle.net/10261/352841 | DOI: | 10.1186/s12985-023-02195-9 | E-ISSN: | 1743-422X | Referencias: | Loucera, Carlos; Carmona, Rosario; Esteban-Medina, Marina; Bostelmann, Gerrit; Muñoyerro-Muñiz, Dolores; Villegas, Román; Peña-Chilet, María; Dopazo, Joaquín. Real-world evidence with a retrospective cohort of 15,968 COVID-19 hospitalized patients suggests 21 new effective treatments. https://doi.org/10.1186/s12985-023-02195-9. http://hdl.handle.net/10261/352838 |
Aparece en las colecciones: | (IBIS) Conjuntos de datos (PTI Salud Global) Colección Especial COVID-19 |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
12985_2023_2195_MOESM1_ESM.pdf | 468,15 kB | Adobe PDF | Visualizar/Abrir | |
12985_2023_2195_MOESM1_ESM_readme.txt | 4,5 kB | Text | Visualizar/Abrir |
CORE Recommender
Este item está licenciado bajo una Licencia Creative Commons